NeoGenomics Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NeoGenomics stock.
View analyst ratings for NeoGenomics or view top-rated stocks.

Wall Street analysts have given NeoGenomics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NeoGenomics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

NeoGenomics is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for NeoGenomics.

NeoGenomics will be holding an earnings conference call on Friday, August 6th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 919-882-2331 with passcode "42174".

NeoGenomics, Inc. (NASDAQ:NEO) posted its earnings results on Wednesday, May, 5th. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.01 by $0.05. The medical research company earned $115.30 million during the quarter, compared to the consensus estimate of $112.17 million. NeoGenomics had a negative net margin of 2.42% and a positive trailing twelve-month return on equity of 0.83%. NeoGenomics's revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the business earned ($0.07) EPS.
View NeoGenomics' earnings history.

NeoGenomics' stock was trading at $24.78 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NEO shares have increased by 86.4% and is now trading at $46.19.
View which stocks have been most impacted by COVID-19.

NeoGenomics declared a dividend on Tuesday, December 15th. Investors of record on Friday, December 18th will be given a dividend of $0.40 per share on Wednesday, December 30th. This represents a dividend yield of 3.13%. The ex-dividend date of this dividend is Thursday, December 17th.
View NeoGenomics' dividend history.

NeoGenomics updated its FY 2021 earnings guidance on Wednesday, May, 26th. The company provided earnings per share guidance of -0.270--0.230 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.200. The company issued revenue guidance of $490 million-$510 million, compared to the consensus revenue estimate of $498.21 million.

10 brokers have issued 12-month target prices for NeoGenomics' shares. Their forecasts range from $14.50 to $65.00. On average, they anticipate NeoGenomics' share price to reach $52.05 in the next year. This suggests a possible upside of 12.7% from the stock's current price.
View analysts' price targets for NeoGenomics or view top-rated stocks among Wall Street analysts.

116 employees have rated NeoGenomics CEO Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among NeoGenomics' employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to NeoGenomics include Alnylam Pharmaceuticals (ALNY), The Cooper Companies (COO), Catalent (CTLT), Bio-Rad Laboratories (BIO.B), Charles River Laboratories International (CRL), UCB (UCBJF), Sartorius Aktiengesellschaft (SARTF), 10x Genomics (TXG), Hologic (HOLX), Fresenius Medical Care AG & Co. KGaA (FME), Sartorius Aktiengesellschaft (SRT), Bio-Techne (TECH), STERIS (STE), Insulet (PODD) and Teleflex (TFX).
View all of NEO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

NeoGenomics' stock is owned by many different institutional and retail investors. Top institutional investors include Emerald Mutual Fund Advisers Trust (0.85%), New York State Common Retirement Fund (0.84%), Granite Investment Partners LLC (0.79%), Emerald Advisers LLC (0.74%), Victory Capital Management Inc. (0.36%) and Redwood Investments LLC (0.30%). Company insiders that own NeoGenomics stock include Bruce K Crowther, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends for NeoGenomics.

NEO stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Oak Ridge Investments LLC, TCW Group Inc., Redwood Investments LLC, Oppenheimer Asset Management Inc., Rice Hall James & Associates LLC, and Handelsbanken Fonder AB. Company insiders that have sold NeoGenomics company stock in the last year include Bruce K Crowther, George Cardoza, Jennifer Balliet, Kevin C Johnson, Lawrence Martin Weiss, Oort Douglas M Van, Robert J Shovlin, Steven C Jones, and William Bonello.
View insider buying and selling activity for NeoGenomics or view top insider-selling stocks.

NEO stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Scout Investments Inc., MAI Capital Management, Alliancebernstein L.P., Exchange Traded Concepts LLC, GWM Advisors LLC, Advisor Group Holdings Inc., and Nkcfo LLC.
View insider buying and selling activity for NeoGenomics or or view top insider-buying stocks.

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NEO stock can currently be purchased for approximately $46.19.

NeoGenomics has a market capitalization of $5.45 billion and generates $444.45 million in revenue each year. The medical research company earns $4.17 million in net income (profit) each year or $0.07 on an earnings per share basis.

NeoGenomics employs 1,700 workers across the globe.

The official website for NeoGenomics is www.neogenomics.com.

NeoGenomics is headquartered at 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913.

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at (239) 768-0600 or via email at [email protected]